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Objective: To investigate predictors of long term prognosis in patients treated for shoulder pain in primary
care.
Methods: Data were taken from two pragmatic randomised clinical trials investigating the effectiveness of
conservative treatments for shoulder pain presenting to primary care. Shoulder pain severity, disability,
and perceived recovery measured in the long term (UK, 18 months; Netherlands, 12 months) were
considered as outcome measures. Prognostic indicators measured before randomisation were determined
by linear regression (pain severity and disability) and logistic regression (perceived recovery).
Results: 316 adults with a new episode of shoulder pain were recruited (UK, n = 207; Netherlands,
n = 109). In multivariate analysis, greater shoulder disability at follow up was associated with higher
baseline disability score, concomitant neck pain, and a gradual onset and longer duration of shoulder
symptoms. Pain scores at follow up were higher in women and in those with longer baseline duration of
symptoms and higher baseline pain or disability scores. Being female, reporting gradual onset of
symptoms, and a higher baseline disability score each independently reduced the likelihood of perceived
recovery.
Conclusions: The results suggest that there is no long term difference in outcome between patients with
shoulder pain treated with different clinical interventions in different clinical settings, or having different
clinical diagnoses. Baseline clinical characteristics of this consulting population, rather than the
randomised treatments which they received, were the most powerful predictors of outcome. Whether
this highlights the need for earlier intervention or reflects different natural histories of shoulder pain is a
topic for further research.
S
houlder problems are common, with up to 47% of adults
in the general population reporting such symptoms in a
one year period.1 In terms of presentation to general
practice, the annual consultation rate for new episodes of
shoulder pain is approximately 1%.2 The current evidence
from both observational studies3–5 and randomised clinical
trials in primary6–8 and secondary care9–10 suggests that many
sufferers have an unfavourable long term outcome, irrespec-
tive of treatment. Identifying those groups of individuals
with shoulder pain who have poor long term outcome would
have several advantages, including the ability to advise
individual patients on their likely course.
The objectives of this analysis were threefold: first, to
investigate the generalisability of the findings from two trials
by determining clinical heterogeneity across the two studies
in terms of participants, interventions, and outcome; second,
to determine the course of shoulder complaints in the
complete sample over the follow up period; and third, to
investigate potential prognostic indicators for poor long term
outcome, using data collected before randomisation.
METHODS
This study used data from two recently completed, pragmatic
randomised clinical trials investigating the effectiveness of
conservative treatments for shoulder pain presenting to
primary care.6 7
Interventions
The trial by Van der Windt et al6 compared the effectiveness of
a local intra-articular injection (by a posterior route) of
40 mg triamcinolone acetonide and a course of physiother-
apy, in 109 participants presenting to primary care in and
around Amsterdam with a new episode of painful stiff
shoulder (capsular syndrome).
The trial by Hay et al7 compared the effectiveness of a
subacromial local corticosteroid injection of 40 mg of
methylprednisolone and 4 ml 1% lignocaine (lidocaine) and
a course of community based physiotherapy. This study was
based in North Staffordshire and randomised a total of 207
participants attending their general practitioner (GP) with a
new episode of shoulder pain. In contrast to the trial of Van
der Windt et al, the participants in the Hay trial had a broad
range of shoulder problems without focus on a particular
diagnosis.
Study population
In both studies, consecutive patients consulting in primary
care for shoulder pain were eligible for recruitment. The
following inclusion criteria were applied in both studies: age
18 years and over, ability to complete questionnaires in the
relevant languages, and able to give informed consent.
Exclusion criteria in both studies included: bilateral symp-
toms, contraindication to the treatments being evaluated,
recent treatment with either a corticosteroid or physiother-
apy, and previous surgery, dislocation, or fracture in the
shoulder area. However Hay et al7 additionally excluded
Abbreviations: NRS, numerical rating scale; RCT, randomised
controlled trial; SDQ, shoulder disability questionnaire; VAS, visual
analogue scale
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patients who had consulted their GP with shoulder pain
during the preceding 12 months.
In both studies, patient characteristics and potential
prognostic factors were recorded by a research nurse at an
initial visit before randomisation. Demographic and clinical
characteristics included age, sex, duration of current shoulder
complaint, and use of painkillers.
Outcome measures
Both studies assessed the following: disability associated
with the shoulder pain; pain severity during the day; and
participants’ perception of the outcome. This information was
collected at three follow up points: short term (six weeks in
the UK, seven weeks in the Netherlands), mid-term (six
months in both studies), and long term (18 months in the
UK, 12 months in the Netherlands). However, there were
minor differences between the two studies in terms of the
scaling used in these three outcome measures.
Different shoulder disability questionnaires (SDQ) were
used in the two studies (SDQ-UK11 and SDQ-NL12). To record
the pain severity, Van der Windt et al6 used a 0–100 visual
analogue scale (VAS), while Hay et al7 used a 10 point
numerical rating scale (NRS). To standardise these two
outcome measures across both studies, measurements from
the Hay study were transformed to 0–100 scales, where 100
indicates maximum pain or disability. The SDQ-UK com-
prises of 23 areas in which shoulder disability is assessed—
for example, fastening clothing, reduced role in household
jobs. To put this transformed 0–100 scale of disability into
context, four points on the 0–100 scale would be approxi-
mately equal to the addition of one more area in which the
participant reported difficulty on the original 23 item version
of the SDQ-UK.
To rate person perceived recovery from baseline, both
studies used a Likert scale, with 5 points for the Hay study
and a 6 point scale for the Van der Windt study. Here, the
scores from both studies were standardised by dichotomising
to two groups into (i) those who had not improved or had
worsened (‘‘unchanged’’, ‘‘worse’’, ‘‘much worse’’), and (ii)
those who had improved (‘‘recovered’’, ‘‘improved’’ (UK);
‘‘recovered’’, ‘‘much improved’’, ‘‘somewhat improved’’
(Netherlands)).
Statistical analysis
We investigated differences between the two study popula-
tions regarding demographic and clinical characteristics
collected at baseline. Summary data were calculated—
proportions for categorical variables and means and standard
deviations for numerical variables. For categorical data,
difference in proportions and their associated 95% confidence
intervals were calculated; for numerical data, mean differ-
ences and their associated 95% confidence intervals (CI) were
calculated. Differences between the two study populations
with regard to baseline pain and disability scores were also
calculated: first, the unadjusted mean differences and 95%
Table 1 Patient characteristics at baseline in two randomised controlled trials on the treatment of shoulder disorders in primary
care
Van der Windt
et al6 (n = 109) Hay et al7 (n = 207) Difference (NL–UK) (95% CI)
Adjusted difference
(95%CI)*
Demographic characteristics
Age (years) 58.8 (10.5) 57.5 (13.4) 1.3 (21.6 to 4.2)
Women 58 (53.2%) 110 (53.1%) 0.07% (211.5% to 11.6%)
Clinical characteristics at baseline
Duration of shoulder complaint (weeks) 27.6 (40.4) 12.5 (15.5) 15.2 (8.9 to 21.4)
Dominant side affected 43 (39.5%) 97 (46.9%) 27.4% (218.8% to 4.0%)
Concomitant neck pain 56 (51.4%) 81 (39.1%) 12.2% (0.7% to 23.7%)
Painkillers in last 48 hours 30 (27.5%) 146 (70.5%) 243.0% (253.4% to 232.6%)
Acute onset of symptoms 24 (22.0%) 58 (28.0%) 26.0% (215.9% to 3.9%)
Baseline measures of outcome
Pain during the day 48.7 (22.1) 56.6 (24.6) 27.9 (213.4 to 22.3) 24.1 (210.3 to 2.1)
Shoulder disability score 69.4 (18.0) 47.4 (19.7) 22.0 (17.5 to 26.5) 25.6 (20.6 to 30.5)
Values are n (%) of participants or mean (SD).
*Linear regression analysis of mean differences (95% confidence intervals) after adjustment for all demographic and clinical characteristics in the table.
Table 2 Patient perceived outcome since baseline
‘‘Improvement’’ since baseline
Van der Windt et al6 (n = 109) Hay et al7 (n = 207)
Injection Physiotherapy Injection Physiotherapy
Short term follow up 50 (96.2%) 44 (78.6%) 69 (72.6%) 77 (78.6%)
Mid-term follow up 44 (84.6%) 47 (87.0%) 80 (82.5%) 82 (85.4%)
Long term follow up 46 (93.9%) 46 (83.6%) 66 (86.6%) 75 (92.6%)
Values are n (%).
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Figure 1 The severity of shoulder disability at baseline and during
follow up for each intervention individually.
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confidence intervals; second, the adjusted mean differences
and 95% CI, allowing for any differences in the demo-
graphic or clinical characteristics between the studies (linear
regression).
Comparisons of the course between the two trials, and
between the two treatment groups within the trials, were
made. Univariate and multivariate analyses were used to
investigate the associations between potential prognostic
indicators and outcome in the long term. For each of the
three outcome measures examined (disability, pain, and
perceived recovery) different models were built, with the
model being parameterised to determine factors associated
with a poor outcome—that is, a higher score for disability or
pain (linear regression) and not improving or worsening
(logistic regression). The variables ‘‘country’’ (Netherlands,
UK) and ‘‘treatment’’ (injection, physiotherapy) were
included in all models as covariates. All putative prognostic
factors showing a univariate association with the outcome at
issue (p,0.10) were put forward into a multivariate analysis
(backward elimination (p,0.10)) to determine a group of
factors that were independently associated with a poor
outcome. We chose this cut off of p,0.1 to represent
significance rather than the more conventional, but no less
arbitrary, value of 0.05, the use of which has been shown to
fail to identify factors known to be of importance.13 Analyses
were carried out using Stata 7.0.14
RESULTS
Study populations
In all, 203 patients were referred from the 60 participating
GPs in the trial based in the Netherlands and 109 (53.7%)
were randomised (56 to physiotherapy and 53 to corticosteroid
injection). Reasons for exclusion were: diagnosis of capsular
syndrome could not be confirmed (n=73), no consent
(n=6), not eligible (n=10), or they had recovered
(n=5).6 In the study by Hay et al,7 207 of 237 patients
(87.3%) referred to the trial by the participating GPs were
randomised (103 to physiotherapy and 104 to corticosteroid
injection). Reasons for exclusion were no consent (n=12),
not eligible (n=11), or they had improved (n=7).
Table 1 presents the baseline demographic and clinical
characteristics and measurements for both studies at base-
line. The two studies were similar with respect to mean age,
proportion of women, proportion with the dominant side
affected, and onset of current symptoms. However, partici-
pants in the trial of Van der Windt et al reported a significant
longer duration of current symptoms, a higher percentage of
concomitant neck pain, and a lower percentage of recent use
of painkillers. With respect to baseline measures of pain and
disability, differences were apparent between the trials.
Disability scores were significantly higher in the Dutch study,
while conversely pain scores were significantly higher in the
UK trial. After adjusting for demographic and clinical
characteristics, the difference in pain severity between the
two studies was reduced. However, the difference in
disability scores persisted after this adjustment.
Course of shoulder symptoms
Despite a significant difference in improvement rates in the
short term for the Dutch trial (difference=17.6% (95% CI,
5.0% to 30.3%)), the pattern of improvement rates was
similar over the longer term both between countries and
between treatments within countries (table 2).
Figure 1 presents the course of ‘‘severity of shoulder
disability’’ for each intervention, separately. At the long term
follow up point (12/18 months), a decrease in disability score
from baseline was seen for almost all participants (90.1%),
regardless of treatment or country. The course of participants
who received a corticosteroid injection was slightly more
favourable in the short term for the Dutch trial, but in the
mid- and long term both treatment groups were similar. The
course for the two treatment groups from the UK trial were
almost identical. Comparing the data from the two countries,
combining the treatment groups, the average disability scores
fell by 68% in the UK trial compared with 57% in the Dutch
trial. Hence, despite a lower long term disability score in the
UK trial, the change from baseline was similar in both trials,
as the Netherlands trial had a greater mean disability score at
recruitment. A similar pattern to that observed for disability
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Figure 2 The severity of shoulder pain during the day at baseline and
during follow up for each intervention individually.
Table 3 Prognostic indicators of the severity of shoulder disability at long term follow up (n = 264): univariate and multivariate
linear regression analyses
Prognostic indicator*
Univariate analysis Multivariate analysis
Mean difference 95% CI Mean difference 95% CI
Age group (years)
20 to 50
51 to 58 6.78 22.94 to 16.5
59 to 67 3.36 26.38 to 13.1
68 to 85 11.06 1.07 to 21.0
Male sex 3.90 22.89 to 10.7
Duration of shoulder pain at baseline (per month) 0.52 0.05 to 1.00 0.52 0.08 to 0.95
Involvement of dominant side 3.04 23.85 to 9.92
Concomitant neck pain 10.70 3.94 to 17.5 6.57 0.21 to 12.9
Gradual onset 6.66 21.19 to 14.5 7.77 0.53 to 15.0
Use of painkillers in previous 48 hours 3.55 23.74 to 10.9
Baseline disability (per point) 0.52 0.36 to 0.67 0.52 0.36 to 0.68
Baseline pain in day (per point) 0.18 0.04 to 0.32
*Adjusted for country and randomised treatment.
CI, confidence interval.
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was seen for pain severity during the day (fig 2). Again,
despite different mean scores at baseline, the UK participants
having higher scores, all four treatment groups had sub-
stantially improved at long term follow up.
Prognostic indicators
Disabili ty score at long term follow up
In the univariate analysis, after adjusting for country and
treatment, the following were all associated with higher
disability score at long term outcome: concomitant neck pain,
gradual onset of symptoms (that is, over a few weeks), longer
duration of symptoms at recruitment, and higher baseline
pain and disability scores (table 3). In the multivariate
analysis, concomitant neck pain, a gradual onset of symp-
toms, longer duration of symptoms at recruitment, and
higher baseline disability score each increased the long term
disability score (R2=23.7%).
At baseline, the mean disability score was 55 points on a
scale of 0–100. By long term follow up this had reduced to a
mean of 21 points. A substantial effect on follow up disability
score was attributable to the presence of concomitant neck
pain at baseline and to a gradual onset of the shoulder sym-
ptoms, with each of these factors being linked to an appro-
ximate 7 point increase in the follow up disability score
among participants with these characteristics compared with
those without. This is equivalent to having two additional areas
of limited everyday functioning reported on the SDQ-UK.
Longer duration of symptoms at baseline also increased
disability score at follow up; comparing two participants,
alike in all other respects, each extra month of recorded
duration would increase the follow up score by 0.5 points.
Not surprisingly, higher disability at baseline led to a higher
score at follow up; this is equivalent to stating that for each
two additional areas of limited everyday functioning recorded
at baseline, one would be retained at follow up.
Pain severity during the day at long term follow up
In the univariate analysis, after adjusting for country and
treatment, the following were associated with higher pain
severity in the day at long term outcome: male sex, longer
duration of symptoms at recruitment, and higher baseline
pain and disability scores (table 4). In the multivariate
analysis, being male, having a longer duration of symptoms
recorded at baseline, and the severity of both baseline pain
and disability scores each independently increased the long
term pain scores (R2= 9.22%).
At baseline, the mean pain score was 54 points on a scale of
0–100. By long term follow up this had reduced to a mean of
13 points. Sex had a substantial effect on follow up pain score
with men having scores 6 points higher than women. As seen
for long term disability, pain severity scores at long term
follow up were higher for those with longer symptom
duration at baseline; each additional six months of duration
Table 4 Prognostic indicators of the severity of shoulder pain during the day at long term follow up (n = 264): univariate and
multivariate linear regression analyses
Prognostic indicator*
Univariate analysis Multivariate analysis
Mean difference 95% CI Mean difference 95% CI
Age group (years)
20 to 50
51 to 58 20.19 27.67 to 7.30
59 to 67 2.29 25.29 to 9.87
68 to 85 6.88 20.81 to 14.6
Male sex 6.06 0.83 to 11.3 5.77 0.74 to 10.8
Duration of shoulder pain at baseline (per month) 0.25 20.13 to 0.62 0.30 20.06 to 0.65
Involvement of dominant side 4.24 21.08 to 9.56
Concomitant neck pain 2.76 22.56 to 8.08
Gradual onset 3.32 22.74 to 9.39
Use of painkillers in previous 48 hours 3.43 22.25 to 9.10
Baseline disability (per point) 0.23 0.10 to 0.36 0.13 0.01 to 0.28
Baseline pain in day (per point) 0.19 0.08 to 0.29 0.15 0.03 to 0.26
*Adjusted for country and randomised treatment.
CI, confidence interval.
Table 5 Prognostic indicators of the perceived outcome of shoulder symptoms at long term follow up (n = 264): univariate and
multivariate logistic regression analyses
Prognostic indicator*
Univariate analysis Multivariate analysis
Odds ratio 95% CI Odds ratio 95% CI
Age group (years)
20 to 50 1.00
51 to 58 0.79 0.24 to 2.60
59 to 67 0.75 0.23 to 2.47
68 to 85 1.50 0.51 to 4.45
Male sex 2.35 1.03 to 5.31 2.57 1.10 to 5.94
Duration of shoulder pain at baseline (per month) 1.03 0.99 to 1.10
Involvement of dominant side 0.90 0.40 to 2.00
Concomitant neck pain 0.96 0.43 to 2.14
Gradual onset 2.98 0.86 to 10.3 3.21 0.91 to 11.3
Use of painkillers in previous 48 hours 1.22 0.52 to 2.86
Baseline disability (per point) 1.03 1.01 to 1.05 1.03 1.01 to 1.05
Baseline pain in day (per point) 1.02 1.00 to 1.03
*Adjusted for country and randomised treatment.
CI, confidence interval.
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at baseline increased the pain score at follow up by
approximately 2 points. Pain at long term follow up was
associated with both baseline pain and disability score.
Perceived recovery at long term
Here, as the outcome measure is dichotomous—that is,
recovered or not recovered—the results are presented as odds
ratios (the odds of not recovering given presence of the risk
factor compared with the odds of not recovering given the
absence of the risk factor). In the univariate analysis, after
adjusting for country and treatment, the following were all
associated with a poor outcome (‘‘not improving’’) at long
term follow up: male sex, gradual onset of symptoms, longer
duration of symptoms at recruitment, and higher baseline
pain and disability scores (table 5). In the multivariate
analysis, being male, reporting a gradual onset of symptoms,
and higher baseline disability scores were independently
associated with not recovering.
Men compared with women, and those who reported a
gradual compared with a sudden onset, were at a threefold
increased odds of not recovering. For each additional point on
the disability score at baseline, the odds of a poor outcome
were increased by 3%; hence for two participants who were
10 disability points apart at baseline, the one with the higher
score would be 30% more likely to have persistent symptoms
at long term follow up.
DISCUSSION
Comparing data from two large recent randomised clinical
trials of shoulder pain in primary care gave us the
opportunity to investigate the generalisability of these
findings. Our analysis confirmed that, as expected from the
inclusion and exclusion criteria, there were differences
between the two study population in terms of their
characteristics at entry to the trial. Despite these differences,
however, the long term effect of treatment appears to be
similar both within each trial and across both trials.
The group of prognostic indicators associated with each of
the outcome measures examined differed with only one
factor (disability score at baseline) common to each model.
Disability, symptom duration and baseline pain level were
the only factors to reach moderate to high evidence for
predicting outcome in a recent systematic review of cohort
studies.15 Prognostic models are unsuitable for making
inferences on interventions to improve prognosis and so the
models derived here are suitable for predicting long term
outcome only—that is, they cannot imply causality.
Some of the heterogeneity seen in the clinical character-
istics of the two study populations partly reflects the different
exclusion criteria and definitions of ‘‘shoulder complaint’’
used. For example, Hay et al,7 unlike Van der Windt et al,6
excluded patients who had previously consulted for the same
shoulder problem in the past 12 months. However, for the
majority of the Dutch participants, the consultation leading
them into the trial was their first in that year period. Van der
Windt et al attempted to assemble a group of patients with a
single diagnosis (capsular syndrome). This differed from the
more general definition of ‘‘shoulder pain’’ as used by Hay et
al. The higher level of baseline shoulder disability and higher
prevalence of concomitant neck pain seen in the Dutch trial
could be related to the different diagnostic criteria used.
Indeed, when a subgroup of UK participants with shoulder
restriction (either in active abduction or external rotation)
was compared to those without restriction, those with
restriction had higher baseline disability scores. The shorter
duration of symptoms at baseline in the UK participants is
likely to reflect the requirement that participants should not
have consulted with their affected shoulder in the previous
12 months.
It is curious that the Dutch participants had higher baseline
disability but lower pain scores that the UK participants. This
finding suggests that the shoulder disability questionnaires
used are indeed measuring something other than pain. This is
likely to be particularly so for the SDQ-UK, which includes
various questions about the more general effects of shoulder
pain on health status (for example, irritability and so on). By
contrast, the SDQ-NL is more restricted in its content,
including questions mainly focusing on the effect of pain on
limitation of function. This finding has been reported
previously, where a higher correlation was seen between the
SDQ-UK and the EuroQol, a generic health outcome measure,
than between the EuroQol and the SDQ-NL.16
There was no evidence from either study that local steroid
injection conferred long term benefit. Local steroid injection
offered some benefit in terms of improvement in short term
pain and disability only in the Dutch trial. This difference
between the trials might relate to different patient selection,
different steroid preparations, or differences in injection
techniques. For example, the majority (75%) of the Dutch
participants randomised to injection received two or three
injections in the treatment period compared to one in the UK
trial.
Pooling data from randomised trials potentially allows for the
detection of important differences in secondary outcome
measures for which the original trials were not individually
powered to detect. In our study such analysis was hampered by
a lack of consistency in the use of outcome measures. Although
we attempted to standardise the two SDQs used in the trials,
there appeared to be some differences relating to the content
these two tools which compromises the validity of this
approach.16 Hence the authors agree that a consensus on a core
set of outcome measures for shoulder pain in needed.16 17
Despite the clinical heterogeneity apparent in the two
study populations, the overall findings of the two trials
suggest that shoulder injection and physiotherapy are
similarly effective in the long term at reducing both pain
and disability in patients presenting to primary care with
shoulder pain. The results of this analysis suggest that there
is no long term difference in outcome between patients
treated with different clinical interventions in different
clinical settings, or having different clinical diagnoses.
Baseline characteristics of the population (gradual onset,
duration and severity of symptoms) were the most powerful
predictors of outcome. This has important implications for
future interventions for shoulder pain; whether it highlights
the need for earlier intervention or reflects different natural
histories of shoulder pain is a topic for further research.
However, the percentage of the variance explained in the
models is quite low, which means that there are other factors
not included in the model (either measured or not measured)
that may explain a further amount of the variability in
outcome among patients with shoulder disorders.
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